History and Development of Sermorelin as a GHRH (1-29) Analog Research Peptide | Palmetto Peptides

History and Development of Sermorelin as a GHRH (1-29) Analog Research Peptide

Research Notice: This article covers research on Sermorelin research peptide and Ipamorelin research peptide — available from Palmetto Peptides for laboratory use only.

Research Use Only Disclaimer: All peptides listed on this page are sold exclusively for in vitro and legitimate laboratory research purposes. They are not intended for human consumption, veterinary use, or any clinical application. The information in this article is for scientific and educational reference only and does not constitute medical advice. All research use must comply with applicable federal, state, and institutional regulations. Palmetto Peptides complies fully with all applicable FDA guidelines.

This article is part of the Complete Sermorelin Research Guide.

Research Disclaimer: Sermorelin is sold exclusively for in vitro and preclinical laboratory research. It is not approved for human or veterinary use. All content is intended for licensed researchers and scientific professionals.

Last Updated: April 14, 2026 | Reading Time: Approximately 7 minutes | Author: Palmetto Peptides Research Team

Quick Answer

History and Development of Sermorelin as a GHRH (1-29) Analog Research Peptide

Direct answer: Sermorelin (GHRH 1-29 NH2) was developed in the early 1980s following the landmark isolation of native growth hormone-releasing hormone (GHRH) from pancreatic tumor tissue. Structure-activity relationship studies quickly revealed that the N-terminal 29 amino acids of GHRH retained full biological activity at the GHRHR receptor, establishing GHRH 1-29 amide — branded as Sermorelin — as a more practical research and pharmaceutical tool than the full 44-amino acid native peptide.

Setting the Stage: The Search for the GH-Releasing Factor

For more than two decades before Sermorelin's development, endocrinologists suspected the existence of a hypothalamic hormone that controlled pituitary GH secretion. Roger Guillemin and Andrew Schally had already won the Nobel Prize in Physiology or Medicine in 1977 for isolating other hypothalamic releasing factors — TRH, LHRH — but GH-releasing factor remained elusive. The primary obstacle was that hypothalamic tissue yields vanishingly small quantities of these peptides, requiring enormous tissue banks to isolate and characterize them.

The breakthrough came from an unexpected source: pancreatic tumor tissue.

1982: Isolation of Native GHRH from Pancreatic Tumor Tissue

In 1982, two independent research groups simultaneously reported the isolation and structural characterization of GHRH:

Roger Guillemin's group at the Salk Institute isolated a 44-amino acid peptide from a human pancreatic islet tumor (from a patient with acromegaly, a condition caused by excess GH) and published in Science.

Wylie Vale and Jean Rivier's group at the Salk Institute, also working from pancreatic tumor extracts, independently characterized a 40-amino acid form of the peptide in Nature.

Both groups confirmed that the isolated peptide stimulated GH release from pituitary cells and represented the long-sought growth hormone-releasing factor (GRF). This discovery opened the door for structure-activity relationship studies and the development of truncated analogs.

Why Pancreatic Tumors?

Ectopic GHRH-secreting tumors (typically pancreatic or bronchial carcinoids) produce GHRH in quantities many orders of magnitude higher than the hypothalamus, making them a practical tissue source for peptide isolation. The acromegaly caused by the tumor — driven by chronic GH excess from ectopic GHRH — was the clinical clue that led researchers to search for a GH-releasing peptide in the tumor tissue.

Structure-Activity Studies: Finding the Active Core

With native GHRH (1-44 and 1-40 forms) in hand, researchers immediately began systematically truncating the sequence to identify the minimal fragment retaining full biological activity. These structure-activity relationship (SAR) studies were conducted throughout the early-to-mid 1980s.

Key Findings

GHRH (1-44) NH2

Full

Native full-length peptide

GHRH (1-40) OH

Tumor-derived form

GHRH (1-29) NH2

Sermorelin — minimal active fragment

GHRH (1-27) NH2

Reduced

Activity begins to drop

GHRH (1-20) NH2

Minimal

Insufficient receptor activation

GHRH (1-44) acid

Amide terminus important

Table 1: Structure-activity relationship findings from early GHRH truncation studies.

The critical finding was that GHRH (1-29) NH2 — the first 29 amino acids with a C-terminal amide — retained full potency at the GHRHR receptor. Fragments shorter than 29 residues showed progressively reduced activity. The C-terminal amide (as opposed to the free acid) was also found to be important for maintaining receptor binding affinity.

This 29-amino acid C-terminally amidated fragment became the canonical minimal active GHRH fragment, the basis for Sermorelin.

Development Timeline

Figure 1: Sermorelin development timeline from GHRH isolation to research peptide status.

The Role of Synthetic Chemistry

The development of Sermorelin as a practical research and pharmaceutical tool was made possible by advances in solid-phase peptide synthesis (SPPS) during the 1970s and 1980s. Bruce Merrifield's development of SPPS (Nobel Prize, 1984) provided the synthetic methodology to produce precise peptide sequences at scale — a capability that made it possible to rapidly test truncated GHRH analogs and manufacture research quantities of the optimized 1-29 fragment.

By the mid-1980s, Sermorelin could be reliably synthesized at research grade with sufficient purity for in vitro and animal model studies, accelerating the body of preclinical literature that established its pharmacological profile.

Sermorelin vs. Other Early GHRH Research Tools

Early GH axis researchers had several peptide tools available, each with different properties:

Native GHRH (1-44)

1982

First characterized; biological standard

GHRH (1-40)

Tumor-derived form; structural reference

Sermorelin (1-29 NH2)

1983-1984

Minimal active fragment; practical research tool

GHRP-6

1984

First synthetic GHRP; GHS-R1a pathway discovery

CJC-1295

2000s

Extended half-life GHRH analog

Table 2: Comparative development of early GH secretagogue research tools.

From Pharmaceutical to Research Peptide

In 1997, Sermorelin acetate was approved by the FDA under the trade name Geref (manufactured by Serono) for use as a diagnostic agent to assess GH secretory capacity in children with suspected GH deficiency. It offered an alternative to insulin tolerance testing (ITT) for stimulating GH secretion in a diagnostic context.

The Geref product was discontinued from the US pharmaceutical market in 2002, reportedly due to commercial and market factors rather than safety or efficacy concerns. This transition effectively moved Sermorelin from the pharmaceutical space back into the research domain, where it has remained a mainstay tool for GH axis studies in academic and preclinical settings.

Today, research-grade Sermorelin is synthesized by specialized peptide chemistry companies and distributed through research peptide suppliers, maintaining rigorous purity standards for use in legitimate laboratory research.

Sermorelin's Scientific Legacy

Sermorelin's development contributed to several foundational advances in endocrinology research:

Established the GHRHR pharmacophore — the minimal sequence needed for receptor binding defined the structural requirements for GHRHR agonists, informing all subsequent GHRH analog development

Enabled systematic GH axis research — a reliable, reproducible synthetic peptide tool for GHRHR studies standardized the field

Informed CJC-1295 and Tesamorelin design — later long-acting GHRH analogs were built on the GHRH 1-29 framework with modifications to extend half-life, using Sermorelin as the structural starting point

Supported aging and GH decline research — Sermorelin's suitability for studying attenuated GH secretion in aged animal models made it a key tool in longevity and geroscience research

Key Research Citations

Guillemin R, et al. "Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly." Science. 1982;218(4572):585-587.

Rivier J, et al. "Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour." Nature. 1982;300(5889):276-278.

Esch FS, et al. "Characterization of a 40 residue peptide from a human pancreatic tumor with growth hormone releasing activity." Biochemical and Biophysical Research Communications. 1982;109(1):152-158.

Lance VA, et al. "Syntheses of growth hormone releasing factor (GRF) and its analogs." Biochemical and Biophysical Research Communications. 1984;119(1):265-272.

Walker RF. "Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?" Clinical Interventions in Aging. 2006;1(4):307-308.

Frequently Asked Questions

When was Sermorelin developed?

Developed in the early 1980s after native GHRH was isolated from pancreatic tumors in 1982. Structure-activity studies by 1983-1984 established GHRH 1-29 NH2 as the minimal active fragment.

Why only 29 amino acids when GHRH is 44?

SAR studies showed residues 1-29 (with C-terminal amide) retain full GHRHR activity. Additional residues 30-44 are non-essential for receptor binding.

Was Sermorelin ever FDA-approved?

Yes, as Geref in 1997 for GH deficiency diagnosis in children. Discontinued commercially in 2002; returned to research use.

Who discovered GHRH?

Roger Guillemin and the Vale/Rivier team at the Salk Institute, independently in 1982, from pancreatic tumor tissue.